Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Gottlieb

Showing results (391-400 of 609) with videos related to

Pageof 61
Sort By:
The British Journal of Dermatology|March 1, 2018
Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3K A Papp, K B Gordon, R G Langley, et al.
Human Molecular Genetics|January 1, 1994
Complete androgen insensitivity due to mutations in the probable alpha-helical segments of the DNA-binding domain in the human androgen receptorL K Beitel, L Prior, D M Vasiliou, et al.
Journal of Drugs in Dermatology : JDD|August 16, 2017
International Dermatology Outcome Measures (IDEOM) Group 2016 New York Meeting: Meeting Summary and Data from the Psoriasis Working GroupLourdes M Perez-Chada, Sanminder Singh, Kristina Callis-Duffin, et al.
Clinical Immunology (Orlando, Fla.)|April 20, 2004
Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasisAlice B Gottlieb, Sewon Kang, Kenneth G Linden, et al.
Journal of the American Academy of Dermatology|January 11, 2003
Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgarisAlice B Gottlieb, Salman Masud, Rallapalli Ramamurthi, et al.
Journal of the American Academy of Dermatology|April 17, 2018
Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)Alice B Gottlieb, Andrew Blauvelt, Diamant Thaçi, et al.
The Journal of Rheumatology|July 15, 2023
Report of the Skin Research Workgroups From the IDEOM Breakout at the GRAPPA 2022 Annual MeetingMelissa P Zundell, Michael J Woodbury, Kathryn Lee, et al.
Journal of the American Academy of Dermatology|September 22, 2020
Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)Mark G Lebwohl, Craig L Leonardi, Nehal N Mehta, et al.
Molecular and Cellular Endocrinology|January 1, 1991
The 56/58 kDa androgen-binding protein in male genital skin fibroblasts with a deleted androgen receptor geneM Trifiro, B Gottlieb, L Pinsky, et al.
The British Journal of Dermatology|August 19, 2014
Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)A Blauvelt, J C Prinz, A B Gottlieb, et al.
Pageof 61

Showing results (391-400 of 609) with videos related to

Sort By:
Pageof 61
The British Journal of Dermatology|March 1, 2018
Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3K A Papp, K B Gordon, R G Langley, et al.
Human Molecular Genetics|January 1, 1994
Complete androgen insensitivity due to mutations in the probable alpha-helical segments of the DNA-binding domain in the human androgen receptorL K Beitel, L Prior, D M Vasiliou, et al.
Journal of Drugs in Dermatology : JDD|August 16, 2017
International Dermatology Outcome Measures (IDEOM) Group 2016 New York Meeting: Meeting Summary and Data from the Psoriasis Working GroupLourdes M Perez-Chada, Sanminder Singh, Kristina Callis-Duffin, et al.
Clinical Immunology (Orlando, Fla.)|April 20, 2004
Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasisAlice B Gottlieb, Sewon Kang, Kenneth G Linden, et al.
Journal of the American Academy of Dermatology|January 11, 2003
Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgarisAlice B Gottlieb, Salman Masud, Rallapalli Ramamurthi, et al.
Journal of the American Academy of Dermatology|April 17, 2018
Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)Alice B Gottlieb, Andrew Blauvelt, Diamant Thaçi, et al.
The Journal of Rheumatology|July 15, 2023
Report of the Skin Research Workgroups From the IDEOM Breakout at the GRAPPA 2022 Annual MeetingMelissa P Zundell, Michael J Woodbury, Kathryn Lee, et al.
Journal of the American Academy of Dermatology|September 22, 2020
Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)Mark G Lebwohl, Craig L Leonardi, Nehal N Mehta, et al.
Molecular and Cellular Endocrinology|January 1, 1991
The 56/58 kDa androgen-binding protein in male genital skin fibroblasts with a deleted androgen receptor geneM Trifiro, B Gottlieb, L Pinsky, et al.
The British Journal of Dermatology|August 19, 2014
Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)A Blauvelt, J C Prinz, A B Gottlieb, et al.
Pageof 61